Ontario drug funding decision leaves cancer patients disappointed, with few options

Read the original at Toronto Star ↗
Cite

Jones, A. (2026, October 21). Ontario drug funding decision leaves cancer patients disappointed, with few options. Toronto Star. https://www.thestar.com/news/ontario/ontario-drug-funding-decision-leaves-cancer-patients-disappointed-with-few-options/article_08e230c0-f785-5471-a23a-41fb6c5618b2.html

Dated from the outlet's own feed. Check the original for its byline.

Toronto Star · collected 2026-10-21 · by Allison Jones

Quick Summary

Ontario’s Health Minister Sylvia Jones announced new regulations limiting out-of-country drug funding for cancer treatments not approved in the province, impacting patients like Sabrina Apitz-Grossman who needs an expensive and potentially life-saving therapy called Tecelra. The government claims this change will save up to $5.2 billion annually, while critics argue it restricts access to critical medications that could extend lives by years. Patients such as Apitz-Grossman feel the decision prioritizes financial considerations over individual health outcomes.
Written locally by qwen2.5:14b on 2026-10-21, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

Sabrina Apitz-Grossman, a 31-year-old cancer patient with 12 to 18 months left to live, was denied coverage for an urgent treatment approved in the United States but unavailable in Ontario. Despite undergoing radiotherapy, chemotherapy, and surgeries, her rare form of synovial sarcoma has spread to her lungs. Her doctors recommend a treatment that OHIP refused to cover through out-of-country coverage or under a special permission program at Princess Margaret Cancer Centre.

The Ontario Health Insurance Plan's decision disappointed many cancer patients who were initially hopeful after Alex Shved won a court challenge against his similar denial. However, Health Minister Sylvia Jones responded by altering the rules in late October 2026, aiming to protect the integrity of Ontario’s drug approval process and avoid up to $5.2 billion in additional costs annually.

Written for “Ontario Cancer Drug Funding Decision” on 2026-10-21, grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
The model judged this article politically coded and scored it -0.45, but all 3 of its quote(s) are attributed speech - words the article quotes from someone, not the article's own narration, so the score is not published.
Written under an earlier scoring contract, which gave a paragraph rather than checkable quotes. Re-analysing this article replaces it.
Leaning score withheld for article 95786: attributed speech only · logged 2026-10-21

Story

📰 Ontario Cancer Drug Funding Decision
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
40
sentences that state something as happening or true
Uncertain
10%
4 of 40 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
63/100
Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-21 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Toronto Star · 8778 article(s) · 23 correction(s) detected
Running correction rate · 23 correction(s)
2026-10-07
Correction
2026-09-24
Correction

Who wrote this

Allison Jones
20 article(s) here · 1 carrying a prediction
🔮 She has undergone radiotherapy, chemotherapy and surgeries, though the synovial sarcoma couldn’t be fully removed.
🔮 While the audit is ongoing, Quinn said, OSAP payments to private postsecondary institutions would be paused.
🔮 While the audit is ongoing, Quinn said, OSAP payments to private post-secondary institutions would be paused.
🔮 Ontario’s colleges and universities ministry is alleging it could not “reliably determine bona fide studies” at two of the career colleges it barred from student financial aid — a decision those schools are now challenging in court.
🔮 An order in May from Nolan Quinn meant that six schools, including four Academy of Learning locations, could not access the Ontario Student Assistance Program for the 2026-27 academic year, which most of them are fighting in court.
🔮 An order in May from Nolan Quinn meant that six schools, including four Academy of Learning locations, could not access the Ontario Student Assistance Program for the 2026-27 academic year, which most of them are fighting in court.
🔮 His cancer has spread to his lungs and his bones and he tried every avenue he could think of to ensure he is around for his daughters as long as possible.
🔮 His cancer has spread to his lungs and his bones and he tried every avenue he could think of to ensure he is around for his daughters as long as possible.
🔮 Ontario government officials who inspected three career colleges found evidence suggesting third parties were completing the coursework — sometimes entire courses in one day — and a few students who couldn't name their school or program, they alleged in reports filed in court.
🔮 Ontario government officials who inspected three career colleges found evidence suggesting third parties were completing the coursework – sometimes entire courses in one day – and a few students who couldn’t name their school or program, they alleged in reports filed in court.
Also by Allison Jones
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 20 articles by Allison Jones →

Topics

Apitz-Grossman Ontario TORONTO the Ontario Health Insurance Plan the United States

Subjects

Apitz-Grossman PERSON · 7× Ontario GPE · 7× Jones PERSON · 2× OHIP ORG · 2× TORONTO GPE · 2× the United States GPE · 2× Ontarians NORP · 1× Sabrina Apitz-Grossman PERSON · 1× the Ontario Health Insurance Plan ORG · 1× the Princess Margaret Cancer Centre ORG · 1×

Narrative

“This change supports a consistent, fair and transparent approach to funding decisions, protects the integrity of Ontario’s world-class drug approval process and will help avoid up to $5.2 billion in additional costs to Ontario’s health-care system every year.” Framing the move as a cost-saving measure is not sitting right with Apitz-Grossman.
framing: assertive · carried by 1 article(s) · first seen 2026-10-21
🔮 She has undergone radiotherapy, chemotherapy and surgeries, though the synovial sarcoma couldn’t be fully removed.

Claims (40 extracted, 4 hedged)

TORONTO - Sabrina Apitz-Grossman was told 13 months ago that she had about 12 to 18 months to live. asserted
she → tell → months
A rare form of cancer in the 31-year-old’s knee had metastasized, spreading to her lungs. asserted
form → metastasize → lungs
She has undergone radiotherapy, chemotherapy and surgeries, though the synovial sarcoma couldn’t be fully removed. asserted
sarcoma → undergo → radiotherapy
Apitz-Grossman’s doctors are recommending a treatment approved in the United States but unavailable in Ontario. asserted
doctors → recommend → Ontario
She needs it urgently but the Ontario Health Insurance Plan turned her down for out-of-country coverage. asserted
Plan → need → coverage
An appeal failed, as did an application under a Case-by-Case Review Program to get special permission for the treatment to be administered at the Princess Margaret Cancer Centre in Toronto. asserted
treatment → fail → Toronto
She is still fighting. asserted
She → fight → ?
“I so desperately would love to turn 32,” she said. asserted
she → love → 32
Apitz-Grossman and other Ontarians with Stage 4 cancer told by their doctors that they are good candidates for treatments unavailable in the province were buoyed last month when 37-year-old Alex Shved, in a similar situation, won a court challenge against his OHIP out-of-country denial. asserted
Shved → tell → denial
But their hopes were dashed when Health Minister Sylvia Jones responded to the court ruling by changing the rules. asserted
Jones → dash → rules
Drug treatments will now only be funded out of country if they are already funded within the province but access is temporarily unavailable or delayed, a set of circumstances some patients see as impossibly narrow. asserted
patients → fund → circumstances
The government said it clarified in regulation what was already long-standing policy. asserted
what → say → regulation
“We’re protecting Ontario patients and taxpayers from price gouging and protecting their access to life-saving medications that would otherwise only be available in the United States or overseas,” Jones wrote in a statement. asserted
Jones → protect → statement
“This change supports a consistent, fair and transparent approach to funding decisions, protects the integrity of Ontario’s world-class drug approval process and will help avoid up to $5.2 billion in additional costs to Ontario’s health-care system every year.” Framing the move as a cost-saving measure is not sitting right with Apitz-Grossman. asserted
Framing → support → Grossman
“Are we saying that we could save like 5,000 or more people’s lives, and they’re proud of themselves for not doing that?” she said. uncertain
she → say → that
“Is this supposed to be good news that we’re not going to save those people, so that we can instead buy a couple more private jets?” asserted
we → suppose → jets
Ontario Premier Doug Ford came under fire earlier this year for a government purchase of a $29-million private jet and quickly returned it. The treatment Apitz-Grossman is seeking, Tecelra, is a personalized therapy made from a patient’s own T-cells, a type of white blood cell. asserted
Grossman → come → cell
Nearly half of patients in Apitz-Grossman’s situation respond to the treatment, and among those who respond, there is a 90 per cent chance of survival after a year and 70 per cent after two years, according to her oncologist. uncertain
who → respond → oncologist
But the treatment is costly, at US$727,000, Apitz-Grossman said. asserted
Grossman → say → 727,000
She feels terrible guilt for seeking such a pricey treatment, she said, but she wants to live. asserted
she → feel → treatment
“There has never been a moment where I have thought to myself, ‘Gosh, I wish that patient who was in the ICU for weeks and who it cost hundreds of thousands of dollars to save, hadn’t been saved,’” Apitz-Grossman said. asserted
Grossman → think → dollars
The origin of Jones’ $5.2-billion figure was unclear in her press release, and a government official later explained that it would be the additional cost if the province entirely stopped negotiating prices with drug manufacturers for public coverage in Ontario. uncertain
province → explain → Ontario
OHIP’s reason for denying Apitz-Grossman, Shved and others out-of-country drug treatment funding is that routinely paying for such requests while drugs are undergoing review for funding in Ontario would “undermine the incentive structure that encourages manufacturers to participate in Canada’s drug review processes.” asserted
that → deny → processes
Kevin Nash, 59, has metastatic melanoma and is seeking the same tumour-infiltrating lymphocyte therapy as Shved. asserted
Nash → have → Shved
Nash’s out-of-country application and subsequent appeal were also denied, and he does not believe the government’s reasoning. asserted
he → deny → reasoning
“These companies make billions of dollars a year, not a billion, billions of dollars a year,” he said. asserted
he → make → dollars
“Do you think that they care one bit whether Kevin Nash goes to Buffalo for a treatment? asserted
Nash → think → treatment
That’s so preposterous.” asserted
That → ’ → ?
In Apitz-Grossman’s case, the manufacturer of Tecelra has said it has no plans to apply for approval in Canada. asserted
it → say → Canada
That means there is no review process in this case to undermine, she noted. asserted
she → mean → case
Holly Wardlow, 61, is in a similar boat, with the government denying coverage through its Case-by-Case Review Program for a medication to treat her rare form of liver cancer because the drug was “expected to be reviewed for public funding in Ontario.” asserted
drug → deny → Ontario
That’s despite the manufacturer submitting two letters telling the province it has no plans to apply for approval in Canada. asserted
it → ’ → Canada
“We just thought, ‘Well, this doesn’t make any sense,’” Wardlow said. asserted
Wardlow → think → sense
“We provided evidence that there is not going to be a population-based review. asserted
We → provide → evidence
This drug is never going to be approved in Canada, let alone Ontario, because the manufacturer is not going to make an application, and they have evidence of that. asserted
they → go → that
And yet they provided the same reason for denying funding. asserted
they → provide → funding
Wardlow and her husband have been paying $78,000 a month for her to receive infusions in Ontario every two weeks, and her tumour has been shrinking with almost no side-effects, she said. asserted
she → pay → effects
Their savings have been depleted and they have now started a GoFundMe. asserted
they → deplete → GoFundMe
“I’m getting out there and trying to stay fit, partly because I can, and partly because the weather is beautiful, and partly because I’m thinking ahead that surgery may be possible in the future,” Wardlow said. uncertain
Wardlow → get → future
This report by The Canadian Press was first published Oct. 21, 2026. asserted
report → publish → Press
💬Give feedback
🕘History 🎫Support